francescalongo

Rare Cancers Europe & JARC at the @EMA_News today discussing the role #ERNs have to play in licensing process of new #rarecancer agents @eurordis, @accrf_org, @SIOPEurope, @cancereu, @ERN_EURACAN, @casali_pg, @theIBTA @myESMO

2nd #ESORareCancers now ending. Done by ESO & ESMO in collaboration with EURACAN & JARC. All 10 families of rare adult solid cancers discussed on a multidisciplinary basis. A patient advocates’ course held in parallel. Let’s think together then how to shape 3rd edition in 2018.

This weekend our trustee @torijanes was in Milan at #ESORareCancers @_rarecancer to talk about patient advocacy @GISTSupportUK and @PAWSGIST

@K1t_G Nuoooo I would have voted for Milan if that counted :/

@myESMO Magnitude of Clinical Scale Munich Workshop Science for Advocates #patientsinvolved

Greetings from Munich! E de Vries talking about ESMO Magnitude of Clinical Benefit Scale - Science for #PatientAdvocates workshop

The ESMO Science for #PatientAdvocates workshop kicking off in Munich, 'Why advocates should care about science' @BettinaRyll

The @ESMO_Open staff wishes you all the most happy holiday season and all the best for 2017! @M_Preusser @cczielinski

Late stage diagnosis one of several contributors to global #cancercare disparities R Stahel @myESMO

@myESMO workshop #cancerpatient networks driving research today & tomorrow #Brussels @cancereu

#Cancer Pat Advocacy Netwks WS: @BettinaRyll welcomes patients keen to drive clinical res bit.ly/23Pg4FE

24/3 MEP Alojz Peterle, Rare Cancers Europe & ESMO event: European Reference Networks #rareCSM @myESMO @lojzepeterle bit.ly/1E8g5ah

Removing Eve’s rare cancer drug also removes hope of finding a cure. #100000voices needed: bit.ly/100000voices

#RareDisease Patient Advocates: Follow These 25 Twitter Accounts | Thank you @eurordis @RareConnect #FF :-) moderators.rareconnect.org/social-media-c…

Our paper on methodological recommendations for clinical studies in #rarecancers now published in Annals of Oncology ow.ly/CeL9I

RT @_rarecancer: A call for new methodologies to be applied to #clinicaltrials in #rarecancers bit.ly/1pry4iD

1 in 5 cancers are #rarecancers #esmo2014 addresses implications for regulatory agenda, clinical decision-making

In a nutshell, methodological challenges: few patients, low level of data, standard of care unclear J Bogaerts #rarecancers

A call for new methodologies to be applied to #clinicaltrials in #rarecancers bit.ly/1pry4iD

ESMO and patient orgs agree on joint policy action to ensure patient access for future conf #ESMO14 #advocatesIN